首页 > 最新文献

Journal of Ocular Pharmacology and Therapeutics最新文献

英文 中文
Solanum nigrum Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model. 黑茄碱的毒性及其通过调节青光眼大鼠模型的细胞外基质对视网膜神经节细胞死亡的神经保护作用
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-06-01 Epub Date: 2024-04-11 DOI: 10.1089/jop.2023.0089
Karan Singh Yadav, Amol Chhatrapati Bisen, Sharmeen Ishteyaque, Isha Sharma, Smriti Verma, Sachin Nashik Sanap, Shobhit Verma, Kaveri R Washimkar, Akhilesh Kumar, Vineeta Tripathi, Rabi Sankar Bhatta, Madhav Nilakanth Mugale

Purpose: Glaucoma is a complex degenerative optic neuropathy characterized by loss of retinal ganglion cells (RGCs) leading to irreversible vision loss and blindness. Solanum nigrum has been used for decades in traditional medicine system. However, no extensive studies were reported on its antiglaucoma properties. Therefore, this study was designed to investigate the neuroprotective effects of S. nigrum extract on RGC against glaucoma rat model. Methods: High performance liquid chromatography and liquid chromatography tandem mass spectrometry was used to analyze the phytochemical profile of aqueous extract of S. nigrum (AESN). In vitro, {3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} (MTT) and H2DCFDA assays were used to determine cell viability and reactive oxygen species (ROS) production in Statens Seruminstitut Rabbit Cornea cells. In vivo, AESN was orally administered to carbomer-induced rats for 4 weeks. Intraocular pressure, antioxidant levels, and electrolytes were determined. Histopathological and immunohistochemical analysis was carried out to evaluate the neurodegeneration of RGC. Results: MTT assay showed AESN exhibited greater cell viability and minimal ROS production at 10 μg/mL. Slit lamp and funduscopy confirmed glaucomatous changes in carbomer-induced rats. Administration of AESN showed minimal peripheral corneal vascularization and restored histopathological alterations such as minimal loss of corneal epithelium and moderate narrowing of the iridocorneal angle. Immunohistochemistry analysis showed increased expression of positive BRN3A cells and decreased matrix metalloproteinase (MMP)-9 activation in retina and cornea, whereas western blot analysis revealed downregulation of extracellular matrix proteins (COL-1 and MMP-9) in AESN-treated rats compared with the diseased group rats. Conclusions: AESN protects RGC loss through remodeling of MMPs and, therefore, can be used for the development of novel neurotherapeutics for the treatment of glaucoma.

目的:青光眼是一种复杂的退行性视神经病变,其特点是视网膜神经节细胞(RGC)丧失,导致不可逆转的视力丧失和失明。几十年来,黑茄科植物一直被用于传统医药系统。然而,没有关于其抗青光眼特性的广泛研究报告。因此,本研究旨在探讨黑千层茄提取物对青光眼大鼠模型 RGC 的神经保护作用。方法:采用高效液相色谱法和液相色谱串联质谱法分析黑升麻水提取物(AESN)的植物化学成分。在体外,采用{3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑}(MTT)和 H2DCFDA 检测法确定 Statens Seruminstitut 兔角膜细胞的细胞活力和活性氧(ROS)产生情况。在体内,给卡波姆诱导的大鼠口服 AESN 4 周。测定眼压、抗氧化剂水平和电解质。通过组织病理学和免疫组化分析来评估 RGC 的神经变性。结果MTT 检测显示,当浓度为 10 μg/mL 时,AESN 的细胞活力更强,产生的 ROS 极少。裂隙灯和眼底检查证实了卡波姆诱导大鼠的青光眼变化。给大鼠注射 AESN 后,其角膜外周血管化极少,组织病理学改变也得到了恢复,如角膜上皮损失极少,虹膜角膜角中度狭窄。免疫组化分析表明,与患病组大鼠相比,AESN 治疗组大鼠视网膜和角膜中 BRN3A 阳性细胞表达增加,基质金属蛋白酶(MMP)-9 激活减少,而 Western 印迹分析表明,AESN 治疗组大鼠细胞外基质蛋白(COL-1 和 MMP-9)下调。结论AESN 可通过重塑 MMP 保护 RGC 的损失,因此可用于开发治疗青光眼的新型神经治疗药物。
{"title":"<i>Solanum nigrum</i> Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model.","authors":"Karan Singh Yadav, Amol Chhatrapati Bisen, Sharmeen Ishteyaque, Isha Sharma, Smriti Verma, Sachin Nashik Sanap, Shobhit Verma, Kaveri R Washimkar, Akhilesh Kumar, Vineeta Tripathi, Rabi Sankar Bhatta, Madhav Nilakanth Mugale","doi":"10.1089/jop.2023.0089","DOIUrl":"10.1089/jop.2023.0089","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Glaucoma is a complex degenerative optic neuropathy characterized by loss of retinal ganglion cells (RGCs) leading to irreversible vision loss and blindness. <i>Solanum nigrum</i> has been used for decades in traditional medicine system. However, no extensive studies were reported on its antiglaucoma properties. Therefore, this study was designed to investigate the neuroprotective effects of <i>S. nigrum</i> extract on RGC against glaucoma rat model. <b><i>Methods:</i></b> High performance liquid chromatography and liquid chromatography tandem mass spectrometry was used to analyze the phytochemical profile of aqueous extract of <i>S. nigrum</i> (AESN). <i>In vitro</i>, {3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} (MTT) and H<sub>2</sub>DCFDA assays were used to determine cell viability and reactive oxygen species (ROS) production in Statens Seruminstitut Rabbit Cornea cells. <i>In vivo</i>, AESN was orally administered to carbomer-induced rats for 4 weeks. Intraocular pressure, antioxidant levels, and electrolytes were determined. Histopathological and immunohistochemical analysis was carried out to evaluate the neurodegeneration of RGC. <b><i>Results:</i></b> MTT assay showed AESN exhibited greater cell viability and minimal ROS production at 10 μg/mL. Slit lamp and funduscopy confirmed glaucomatous changes in carbomer-induced rats. Administration of AESN showed minimal peripheral corneal vascularization and restored histopathological alterations such as minimal loss of corneal epithelium and moderate narrowing of the iridocorneal angle. Immunohistochemistry analysis showed increased expression of positive BRN3A cells and decreased matrix metalloproteinase (MMP)-9 activation in retina and cornea, whereas western blot analysis revealed downregulation of extracellular matrix proteins (COL-1 and MMP-9) in AESN-treated rats compared with the diseased group rats. <b><i>Conclusions:</i></b> AESN protects RGC loss through remodeling of MMPs and, therefore, can be used for the development of novel neurotherapeutics for the treatment of glaucoma.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"309-324"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia. 不同浓度的低剂量阿托品对近视儿童瞳孔直径和屈光度的影响
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-04-15 DOI: 10.1089/jop.2023.0173
Huy D M Tran, Thao T X Ha, Yen H Tran, Minas Coroneo, Tuan D Tran, Trang U Truong, Padmaja Sankaridurg

Purpose: To assess over 2 weeks, the effect of 3 different low concentrations of atropine on pupillary diameter and accommodative amplitude in children with myopia. Methods: Fifty-eight children with myopia [spherical equivalent (SE) of -0.50 diopters (D) or worse, astigmatism of less than or equal to 2.00 D] were randomly allocated to 3 groups receiving 0.01%, 0.02%, or 0.03% atropine eye drops, once nightly for 2 weeks. The primary outcome was the change from baseline in pupillary diameter and accommodative amplitude with each of the concentrations. Results: Fifty-seven participants (114 eyes), aged between 6 and 12 years, completed the 2-week trial (mean age 9.3 ± 1.7 years and mean SE -3.53 ± 1.79 D). After 2 weeks of use, all the 3 concentrations were found to have a statistically significant effect on both the pupillary diameter and accommodative amplitude. Accommodative amplitude reduced by an average of 5.23 D, 9.28 D, and 9.32 D, and photopic pupil size increased by an average of 0.95 ± 1.05 mm, 1.65 ± 0.93 mm, and 2.16 ± 0.88 mm with 0.01%, 0.02%, and 0.03%, respectively. Of the eyes, a total of 5.3% and 5.9% of the eyes on 0.02% and 0.03% atropine had a mean residual accommodative amplitude of <5 D. The percentage of eyes having a pupillary dilation >3 mm were 4.8%, 10.5%, and 23.5% for 0.01%, 0.02%, and 0.03% atropine, respectively. Conclusions: Low-dose atropine had an effect on pupillary diameter and accommodative amplitude. With the highest concentration assessed, that is, 0.03% nearly 1 of 4 eyes had pupillary dilation of >3 mm. Clinical Trial Registration number: NCT03699423.

目的:在两周内评估 3 种不同低浓度阿托品对近视儿童瞳孔直径和容纳幅度的影响。方法:对 58 名近视儿童(球面等效度数为 1.0 或 1.0 以上)进行测试:将 58 名近视儿童[球面等效度数(SE)为-0.50 屈光度(D)或更差,散光小于或等于 2.00 屈光度]随机分配到 3 组,分别滴用 0.01%、0.02% 或 0.03% 的阿托品眼药水,每晚一次,持续 2 周。主要结果是每种浓度的瞳孔直径和屈光幅度与基线相比的变化。研究结果57名参与者(114只眼睛)完成了为期2周的试验,他们的年龄在6至12岁之间(平均年龄为9.3 ± 1.7岁,平均SE为-3.53 ± 1.79 D)。使用 2 周后,发现所有 3 种浓度的药物对瞳孔直径和屈光幅度都有显著的统计学影响。使用 0.01%、0.02% 和 0.03% 时,屈光幅度分别平均减小 5.23 D、9.28 D 和 9.32 D,光瞳直径分别平均增大 0.95 ± 1.05 mm、1.65 ± 0.93 mm 和 2.16 ± 0.88 mm。在使用 0.02% 和 0.03% 阿托品的眼睛中,分别有 5.3% 和 5.9% 的眼睛的平均残余容纳振幅为 3 毫米,而使用 0.01%、0.02% 和 0.03% 阿托品的眼睛的平均残余容纳振幅分别为 4.8%、10.5% 和 23.5%。结论小剂量阿托品对瞳孔直径和容纳振幅有影响。在评估的最高浓度(即 0.03%)下,4 只眼睛中有近 1 只的瞳孔扩张大于 3 毫米。临床试验注册号:NCT03699423:NCT03699423。
{"title":"Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.","authors":"Huy D M Tran, Thao T X Ha, Yen H Tran, Minas Coroneo, Tuan D Tran, Trang U Truong, Padmaja Sankaridurg","doi":"10.1089/jop.2023.0173","DOIUrl":"10.1089/jop.2023.0173","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To assess over 2 weeks, the effect of 3 different low concentrations of atropine on pupillary diameter and accommodative amplitude in children with myopia. <b><i>Methods:</i></b> Fifty-eight children with myopia [spherical equivalent (SE) of -0.50 diopters (D) or worse, astigmatism of less than or equal to 2.00 D] were randomly allocated to 3 groups receiving 0.01%, 0.02%, or 0.03% atropine eye drops, once nightly for 2 weeks. The primary outcome was the change from baseline in pupillary diameter and accommodative amplitude with each of the concentrations. <b><i>Results:</i></b> Fifty-seven participants (114 eyes), aged between 6 and 12 years, completed the 2-week trial (mean age 9.3 ± 1.7 years and mean SE -3.53 ± 1.79 D). After 2 weeks of use, all the 3 concentrations were found to have a statistically significant effect on both the pupillary diameter and accommodative amplitude. Accommodative amplitude reduced by an average of 5.23 D, 9.28 D, and 9.32 D, and photopic pupil size increased by an average of 0.95 ± 1.05 mm, 1.65 ± 0.93 mm, and 2.16 ± 0.88 mm with 0.01%, 0.02%, and 0.03%, respectively. Of the eyes, a total of 5.3% and 5.9% of the eyes on 0.02% and 0.03% atropine had a mean residual accommodative amplitude of <5 D. The percentage of eyes having a pupillary dilation >3 mm were 4.8%, 10.5%, and 23.5% for 0.01%, 0.02%, and 0.03% atropine, respectively. <b><i>Conclusions:</i></b> Low-dose atropine had an effect on pupillary diameter and accommodative amplitude. With the highest concentration assessed, that is, 0.03% nearly 1 of 4 eyes had pupillary dilation of >3 mm. Clinical Trial Registration number: NCT03699423.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"232-239"},"PeriodicalIF":1.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model. 在角膜碱烧伤兔模型中评估人眼眶脂肪来源干细胞条件培养基的治疗效果
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-28 DOI: 10.1089/jop.2023.0154
Yu Cheng, Guangpeng Liu

Purpose: This study aimed to evaluate the effects of a new treatment-conditioned medium from human orbital adipose-derived stem cells (OASC-CM)-on corneal recovery after alkali burns in a rabbit model. Methods: The corneal alkali burn rabbit model was established and treated with OASC-CM, conditioned medium from human abdominal subcutaneous adipose-derived stem cells (ABASC-CM), and fresh control culture medium (con-CM) three times a day for 7 days, respectively. Subsequently, the treatment effects were evaluated and compared through clinical, histological, immunohistochemical, and cytokine evaluations. Results: Clinically, OASC-CM alleviated corneal opacity and edema and promoted recovery of corneal epithelium defect. Histologically and immunohistochemically, OASC-CM inhibited neovascularization, conjunctivalization, and immuno-inflammatory reaction, while promoting corneal regeneration and rearrangement. Increased secretion of interleukin-10 and inhibited protein levels of cluster of differentiation 45, interferon-γ, and tumor necrosis factor-α were observed in the alkali-burned cornea after OASC-CM treatment, which might be the relevant molecular mechanism. Conclusions: OASC-CM showed significant effects on the recovery of rabbit corneal alkali burns and eliminated immunological and ethical limitations, representing a new option for corneal wound treatment.

目的:本研究旨在评估一种新的治疗方法--人眼眶脂肪衍生干细胞调理培养基(OASC-CM)--对兔子模型碱烧伤后角膜恢复的影响。方法:建立碱烧伤兔角膜模型,分别用OASC-CM、人腹部皮下脂肪衍生干细胞条件培养基(ABASC-CM)和新鲜对照培养基(con-CM)治疗,每天三次,连续7天。随后,通过临床、组织学、免疫组化和细胞因子评估来评价和比较治疗效果。结果在临床上,OASC-CM 可减轻角膜混浊和水肿,促进角膜上皮缺损的恢复。从组织学和免疫组化角度看,OASC-CM 可抑制新生血管、结膜化和免疫炎症反应,同时促进角膜再生和重新排列。OASC-CM 治疗后,碱烧伤角膜的白细胞介素-10 分泌增加,分化簇 45、干扰素-γ 和肿瘤坏死因子-α 的蛋白水平受到抑制,这可能是相关的分子机制。结论OASC-CM 对兔碱烧伤角膜的恢复有显著效果,并消除了免疫学和伦理学方面的限制,是角膜创面治疗的一种新选择。
{"title":"Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model.","authors":"Yu Cheng, Guangpeng Liu","doi":"10.1089/jop.2023.0154","DOIUrl":"10.1089/jop.2023.0154","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> This study aimed to evaluate the effects of a new treatment-conditioned medium from human orbital adipose-derived stem cells (OASC-CM)-on corneal recovery after alkali burns in a rabbit model. <b><i>Methods:</i></b> The corneal alkali burn rabbit model was established and treated with OASC-CM, conditioned medium from human abdominal subcutaneous adipose-derived stem cells (ABASC-CM), and fresh control culture medium (con-CM) three times a day for 7 days, respectively. Subsequently, the treatment effects were evaluated and compared through clinical, histological, immunohistochemical, and cytokine evaluations. <b><i>Results:</i></b> Clinically, OASC-CM alleviated corneal opacity and edema and promoted recovery of corneal epithelium defect. Histologically and immunohistochemically, OASC-CM inhibited neovascularization, conjunctivalization, and immuno-inflammatory reaction, while promoting corneal regeneration and rearrangement. Increased secretion of interleukin-10 and inhibited protein levels of cluster of differentiation 45, interferon-γ, and tumor necrosis factor-α were observed in the alkali-burned cornea after OASC-CM treatment, which might be the relevant molecular mechanism. <b><i>Conclusions:</i></b> OASC-CM showed significant effects on the recovery of rabbit corneal alkali burns and eliminated immunological and ethical limitations, representing a new option for corneal wound treatment.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"222-231"},"PeriodicalIF":2.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement. 比较 Proparacaine、Tetracaine 和 Oxybuprocaine 在角膜敏感度测量中的作用。
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-04-08 DOI: 10.1089/jop.2023.0148
Paula Basso Dias, Marta Dos Anjos Rodrigues Parchen, Daniel Wasilewski

Purpose: This study aimed to determine the onset and duration of action of 3 commercially available topical anesthetic solutions in Brazil, using the Cochet-Bonnet esthesiometer (Luneau®, Paris, France) and to quantitatively assess patient-reported discomfort during application. Methods: A prospective, randomized, masked, and double-blind study was conducted, involving 40 eyes from 21 patients. Patients were administered each one of the topical anesthetics weekly, and corneal sensitivity was measured using the Cochet-Bonnet esthesiometer's corneal touch threshold (CTT). Patients rated the burning sensation using a visual analogue scale (VAS). Results: Among the 21 patients (42.9% male), with a mean age of 31.95 years (±standard deviation = 10.17, range = 22.0-58.0), corneal sensitivity significantly decreased 30 s after application, returning to baseline after 30 min for all groups (P < 0.0001). Significant differences in CTT were observed at 5 min, with proparacaine exhibiting a superior anesthetic effect (P = 0.0003), at 10 min, where tetracaine displayed the most substantial anesthetic effect (P = 0.0135), and at 20 min, where tetracaine demonstrated the highest anesthetic efficacy (P < 0.0001). VAS scores indicated the most intense burning sensation with tetracaine (P < 0.0001). Men reported experiencing more discomfort during instillation compared with women (P = 0.0168). Conclusions: Proparacaine exhibited the fastest onset of action among the 3 topical anesthetics and provided a more comfortable eye sensation during instillation. However, tetracaine demonstrated the longest duration of action despite causing more discomfort.

目的:本研究旨在使用 Cochet-Bonnet 血压计(Luneau®,法国巴黎)确定巴西市场上 3 种外用麻醉剂溶液的起效时间和作用持续时间,并定量评估患者报告的使用过程中的不适感。研究方法进行了一项前瞻性、随机、蒙面和双盲研究,涉及 21 名患者的 40 只眼睛。患者每周使用一种局部麻醉剂,并使用 Cochet-Bonnet 角膜触觉阈值(CTT)测量角膜敏感度。患者使用视觉模拟量表(VAS)对灼烧感进行评分。结果:在 21 名平均年龄为 31.95 岁(± 标准差 = 10.17,范围 = 22.0-58.0)的患者(42.9% 为男性)中,角膜敏感度在用药 30 秒后显著下降,30 分钟后所有组别均恢复至基线(P P = 0.0003),10 分钟时四卡因的麻醉效果最好(P = 0.0135),20 分钟时四卡因的麻醉效果最好(P P = 0.0168)。结论在三种局部麻醉剂中,丙美卡因起效最快,而且在灌注过程中眼睛感觉更舒适。不过,尽管四卡因会引起更多不适,但其作用持续时间却最长。
{"title":"Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement.","authors":"Paula Basso Dias, Marta Dos Anjos Rodrigues Parchen, Daniel Wasilewski","doi":"10.1089/jop.2023.0148","DOIUrl":"10.1089/jop.2023.0148","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> This study aimed to determine the onset and duration of action of 3 commercially available topical anesthetic solutions in Brazil, using the Cochet-Bonnet esthesiometer (Luneau<sup>®</sup>, Paris, France) and to quantitatively assess patient-reported discomfort during application. <b><i>Methods:</i></b> A prospective, randomized, masked, and double-blind study was conducted, involving 40 eyes from 21 patients. Patients were administered each one of the topical anesthetics weekly, and corneal sensitivity was measured using the Cochet-Bonnet esthesiometer's corneal touch threshold (CTT). Patients rated the burning sensation using a visual analogue scale (VAS). <b><i>Results:</i></b> Among the 21 patients (42.9% male), with a mean age of 31.95 years (±standard deviation = 10.17, range = 22.0-58.0), corneal sensitivity significantly decreased 30 s after application, returning to baseline after 30 min for all groups (<i>P</i> < 0.0001). Significant differences in CTT were observed at 5 min, with proparacaine exhibiting a superior anesthetic effect (<i>P</i> = 0.0003), at 10 min, where tetracaine displayed the most substantial anesthetic effect (<i>P</i> = 0.0135), and at 20 min, where tetracaine demonstrated the highest anesthetic efficacy (<i>P</i> < 0.0001). VAS scores indicated the most intense burning sensation with tetracaine (<i>P</i> < 0.0001). Men reported experiencing more discomfort during instillation compared with women (<i>P</i> = 0.0168). <b><i>Conclusions:</i></b> Proparacaine exhibited the fastest onset of action among the 3 topical anesthetics and provided a more comfortable eye sensation during instillation. However, tetracaine demonstrated the longest duration of action despite causing more discomfort.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"215-221"},"PeriodicalIF":1.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Insulin for Ocular Surface Disease. 治疗眼表疾病的局部胰岛素。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-22 DOI: 10.1089/jop.2024.0016
Pau Cid-Bertomeu, Magí Vilaltella, Mireia Martínez, Marta Mir, Valentín Huerva

Background: Insulin and insulin-like growth factor (IGF)-1 receptors are present in ocular tissues such as corneal epithelium, keratocytes, and conjunctival cells. Insulin plays a crucial role in the growth, differentiation, and proliferation of corneal epithelial cells, as well as in wound healing processes in various tissues. Purpose: This review explores the potential role of topical insulin in the treatment of ocular surface diseases. Specifically, it examines its impact on corneal nerve regeneration, sub-basal plexus corneal nerves, and its application in conditions like corneal epithelial defects, dry eye disease, and diabetic keratopathy. Methods: The review analyzes studies conducted over the past decade that have investigated the use of topical insulin in ocular surface diseases. It focuses on indications, drug preparation methods, side effects, efficacy outcomes, and variations in insulin concentrations and dosages used. Results: While off-label use of topical insulin has shown promising results in refractory corneal epithelial defects, its efficacy in dry eye disease is yet to be demonstrated. Variations in concentrations, dilutions, and dosing guidelines have been reported. However, limited data on ocular penetration, ocular toxicity, and systemic side effects pose challenges to its widespread utility. Conclusion: This review synthesizes findings from ocular investigations on topical insulin to assess its potential applicability in treating ocular surface and corneal diseases. By highlighting indications, preparation methods, side effects, and efficacy outcomes, it aims to provide insights into the current status and future prospects of using topical insulin in ophthalmic practice.

背景:胰岛素和胰岛素样生长因子(IGF)-1 受体存在于角膜上皮细胞、角膜细胞和结膜细胞等眼组织中。胰岛素在角膜上皮细胞的生长、分化和增殖以及各种组织的伤口愈合过程中发挥着至关重要的作用。目的:本综述探讨了局部胰岛素在治疗眼表疾病中的潜在作用。具体而言,它研究了胰岛素对角膜神经再生、基底丛下角膜神经的影响,以及在角膜上皮缺损、干眼症和糖尿病角膜病变等疾病中的应用。方法:本综述分析了过去十年间对局部胰岛素在眼表疾病中应用的研究。重点关注适应症、药物制备方法、副作用、疗效结果以及所用胰岛素浓度和剂量的变化。结果:虽然标签外使用胰岛素治疗难治性角膜上皮缺损取得了良好效果,但其对干眼症的疗效仍有待证实。有报告称,胰岛素的浓度、稀释度和剂量指南存在差异。然而,有关眼部渗透、眼部毒性和全身副作用的数据有限,这对其广泛应用构成了挑战。结论本综述综合了有关局部胰岛素的眼部研究结果,以评估其在治疗眼表和角膜疾病方面的潜在适用性。通过强调适应症、制备方法、副作用和疗效结果,旨在为眼科实践中局部使用胰岛素的现状和未来前景提供见解。
{"title":"Topical Insulin for Ocular Surface Disease.","authors":"Pau Cid-Bertomeu, Magí Vilaltella, Mireia Martínez, Marta Mir, Valentín Huerva","doi":"10.1089/jop.2024.0016","DOIUrl":"10.1089/jop.2024.0016","url":null,"abstract":"<p><p><b><i>Background:</i></b> Insulin and insulin-like growth factor (IGF)-1 receptors are present in ocular tissues such as corneal epithelium, keratocytes, and conjunctival cells. Insulin plays a crucial role in the growth, differentiation, and proliferation of corneal epithelial cells, as well as in wound healing processes in various tissues. <b><i>Purpose:</i></b> This review explores the potential role of topical insulin in the treatment of ocular surface diseases. Specifically, it examines its impact on corneal nerve regeneration, sub-basal plexus corneal nerves, and its application in conditions like corneal epithelial defects, dry eye disease, and diabetic keratopathy. <b><i>Methods:</i></b> The review analyzes studies conducted over the past decade that have investigated the use of topical insulin in ocular surface diseases. It focuses on indications, drug preparation methods, side effects, efficacy outcomes, and variations in insulin concentrations and dosages used. <b><i>Results:</i></b> While off-label use of topical insulin has shown promising results in refractory corneal epithelial defects, its efficacy in dry eye disease is yet to be demonstrated. Variations in concentrations, dilutions, and dosing guidelines have been reported. However, limited data on ocular penetration, ocular toxicity, and systemic side effects pose challenges to its widespread utility. <b><i>Conclusion:</i></b> This review synthesizes findings from ocular investigations on topical insulin to assess its potential applicability in treating ocular surface and corneal diseases. By highlighting indications, preparation methods, side effects, and efficacy outcomes, it aims to provide insights into the current status and future prospects of using topical insulin in ophthalmic practice.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"204-214"},"PeriodicalIF":2.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140288395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eyes on New Product Development. 关注新产品开发。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-04-30 DOI: 10.1089/jop.2024.0066
Gary D Novack
{"title":"Eyes on New Product Development.","authors":"Gary D Novack","doi":"10.1089/jop.2024.0066","DOIUrl":"10.1089/jop.2024.0066","url":null,"abstract":"","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"203"},"PeriodicalIF":2.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension. 两种固定剂量抗青光眼药物组合布林佐胺-溴莫尼定与拉坦前列素-噻吗洛尔在原发性开角型青光眼和眼压过高症中降低眼压疗效的比较研究
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-04-10 DOI: 10.1089/jop.2023.0186
Avinash Mishra, Mohini Agrawal, Anchal Tripathi, Atul Bhirud, Lt Col Rajnish Kumar, Brig Baranwal Vinod K

Purpose: To compare the efficacy of Brinzolamide-Brimonidine (BB) (1%+0.2%) with the gold standard Latanoprost-Timolol (LT) (0.005%+0.5%) in treating primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Methods: A 1-year prospective study, spanning from May 2022 to May 2023, conducted at a tertiary eye-care hospital. Participants, aged 40-60, with a baseline intraocular pressure (IOP) >21 mm Hg, requiring a >30% reduction, were enrolled. Group A (n = 100) received BB, and Group B (n = 100) received LT. Outcomes were assessed at 1 month (IOP difference from baseline), 3 and 6 months (mean diurnal variations). Results: The mean age at presentation was 55.5 ± 4.5 years in Group A and 54.7 ± 4.2 years in Group B. At 1 month, Group A exhibited a mean IOP of 18.7 mm Hg, while Group B had 17.6 mm Hg, with no statistically significant difference (P = 0.53). No significant diurnal variation was observed in either group (P = 0.07). Target pressure was achieved in 88% of patients in Group A and slightly higher at 92% in Group B. Moreover, no serious side effects were reported, and compliance was higher in Group B (98%) compared to Group A (96%). Conclusion: Although LT showed slightly better and sustained IOP reduction, the difference was not statistically significant. Both BB and LT demonstrated comparable outcomes for managing POAG and OHT.

目的:比较布林佐胺-溴莫尼定(BB)(1%+0.2%)与金标准拉坦前列素-噻吗洛尔(LT)(0.005%+0.5%)治疗原发性开角型青光眼(POAG)和眼压过高(OHT)的疗效。研究方法一项为期 1 年的前瞻性研究,时间跨度为 2022 年 5 月至 2023 年 5 月,在一家三级眼科医院进行。参与者年龄在 40-60 岁之间,基线眼压(IOP)大于 21 mm Hg,需要降低大于 30% 的眼压。A组(100人)接受BB治疗,B组(100人)接受LT治疗。结果在 1 个月(眼压与基线的差异)、3 个月和 6 个月(平均昼夜变化)时进行评估。结果:1 个月时,A 组的平均眼压为 18.7 mm Hg,B 组为 17.6 mm Hg,差异无统计学意义(P = 0.53)。两组均未观察到明显的昼夜变化(P = 0.07)。此外,没有严重副作用的报告,B 组的依从性(98%)高于 A 组(96%)。结论虽然LT治疗的眼压降低效果稍好且持续时间较长,但差异无统计学意义。BB和LT治疗POAG和OHT的效果相当。
{"title":"A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.","authors":"Avinash Mishra, Mohini Agrawal, Anchal Tripathi, Atul Bhirud, Lt Col Rajnish Kumar, Brig Baranwal Vinod K","doi":"10.1089/jop.2023.0186","DOIUrl":"10.1089/jop.2023.0186","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To compare the efficacy of Brinzolamide-Brimonidine (BB) (1%+0.2%) with the gold standard Latanoprost-Timolol (LT) (0.005%+0.5%) in treating primary open-angle glaucoma (POAG) and ocular hypertension (OHT). <b><i>Methods:</i></b> A 1-year prospective study, spanning from May 2022 to May 2023, conducted at a tertiary eye-care hospital. Participants, aged 40-60, with a baseline intraocular pressure (IOP) >21 mm Hg, requiring a >30% reduction, were enrolled. Group A (<i>n</i> = 100) received BB, and Group B (<i>n</i> = 100) received LT. Outcomes were assessed at 1 month (IOP difference from baseline), 3 and 6 months (mean diurnal variations). <b><i>Results:</i></b> The mean age at presentation was 55.5 ± 4.5 years in Group A and 54.7 ± 4.2 years in Group B. At 1 month, Group A exhibited a mean IOP of 18.7 mm Hg, while Group B had 17.6 mm Hg, with no statistically significant difference (<i>P</i> = 0.53). No significant diurnal variation was observed in either group (<i>P</i> = 0.07). Target pressure was achieved in 88% of patients in Group A and slightly higher at 92% in Group B. Moreover, no serious side effects were reported, and compliance was higher in Group B (98%) compared to Group A (96%). <b><i>Conclusion:</i></b> Although LT showed slightly better and sustained IOP reduction, the difference was not statistically significant. Both BB and LT demonstrated comparable outcomes for managing POAG and OHT.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"240-245"},"PeriodicalIF":2.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity. 通过阻断具有 PDZ 结合基元活性的是相关蛋白/转录辅激活因子,抑制成人视网膜色素上皮-19 细胞中结缔组织生长因子的表达。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-22 DOI: 10.1089/jop.2023.0141
Yoko Murakami, Toshiyasu Imaizumi, Kouhei Hashizume, Yu Tezuka, Yusuke Oku, Naoyuki Nishiya, Atsushi Sanbe, Daijiro Kurosaka

Purpose: To investigate the effect of yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) on connective tissue growth factor (CTGF) expression in adult retinal pigment epithelial (ARPE)-19 cells. We also studied the inhibitory effect of K-975, a new pan-transcriptional enhanced associate domain (TEAD) inhibitor, and luteolin, a plant-derived flavonoid on CTGF expression. Methods: ARPE-19 cells were transfected with either YAP or TAZ overexpression plasmid or treated with transforming growth factor (TGF)-β2. The cells were cultured either with or without K-975 or luteolin. The expression of YAP, TAZ, and CTGF was examined using real-time PCR. Results: ARPE-19 cells overexpressing YAP or TAZ exhibited significantly increased CTGF expression. This increase was attenuated by K-975 or luteolin alone. TGF-β2 treatment significantly raised the expression of not just YAP and TAZ, but also CTGF in ARPE-19 cells. TGF-β2 treatment-enhanced CTGF expression was considerably lowered by the addition of K-975 or luteolin. Conclusions: Overexpression of YAP or TAZ and treatment with TGF-β2 led to an increase in the expression of CTGF in ARPE-19 cells. These increases were attenuated by treatment with K-975 and luteolin. These findings suggest that YAP and TAZ may be related to the expression of CTGF in ARPE-19 cells and that K-975 and luteolin can be explored as potential therapeutic agents for preventing CTGF production in vitreoretinal fibrosis.

目的:研究是相关蛋白(YAP)和具有 PDZ 结合基调的转录辅激活因子(TAZ)对成人视网膜色素上皮(ARPE)-19 细胞中结缔组织生长因子(CTGF)表达的影响。我们还研究了新型泛转录增强关联域(TEAD)抑制剂 K-975 和植物黄酮类化合物木犀草素对 CTGF 表达的抑制作用。研究方法用YAP或TAZ过表达质粒转染ARPE-19细胞,或用转化生长因子(TGF)-β2处理ARPE-19细胞。使用或不使用 K-975 或叶黄素培养细胞。使用实时 PCR 检测 YAP、TAZ 和 CTGF 的表达。结果显示过表达 YAP 或 TAZ 的 ARPE-19 细胞的 CTGF 表达明显增加。K-975 或单用木犀草素可减轻这种增加。TGF-β2 处理不仅能显著提高 YAP 和 TAZ 的表达,还能显著提高 CTGF 在 ARPE-19 细胞中的表达。加入 K-975 或叶黄素后,TGF-β2 处理增强的 CTGF 表达量大大降低。结论过表达 YAP 或 TAZ 以及 TGF-β2 处理会导致 ARPE-19 细胞中 CTGF 的表达增加。用 K-975 和叶黄素处理可减轻这些增加。这些研究结果表明,YAP和TAZ可能与ARPE-19细胞中CTGF的表达有关,K-975和木犀草素可作为潜在的治疗药物,用于防止玻璃体视网膜纤维化中CTGF的产生。
{"title":"Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.","authors":"Yoko Murakami, Toshiyasu Imaizumi, Kouhei Hashizume, Yu Tezuka, Yusuke Oku, Naoyuki Nishiya, Atsushi Sanbe, Daijiro Kurosaka","doi":"10.1089/jop.2023.0141","DOIUrl":"10.1089/jop.2023.0141","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To investigate the effect of yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) on connective tissue growth factor (CTGF) expression in adult retinal pigment epithelial (ARPE)-19 cells. We also studied the inhibitory effect of K-975, a new pan-transcriptional enhanced associate domain (TEAD) inhibitor, and luteolin, a plant-derived flavonoid on CTGF expression. <b><i>Methods:</i></b> ARPE-19 cells were transfected with either YAP or TAZ overexpression plasmid or treated with transforming growth factor (TGF)-β<sub>2</sub>. The cells were cultured either with or without K-975 or luteolin. The expression of YAP, TAZ, and CTGF was examined using real-time PCR. <b><i>Results:</i></b> ARPE-19 cells overexpressing YAP or TAZ exhibited significantly increased CTGF expression. This increase was attenuated by K-975 or luteolin alone. TGF-β<sub>2</sub> treatment significantly raised the expression of not just YAP and TAZ, but also CTGF in ARPE-19 cells. TGF-β<sub>2</sub> treatment-enhanced CTGF expression was considerably lowered by the addition of K-975 or luteolin. <b><i>Conclusions:</i></b> Overexpression of YAP or TAZ and treatment with TGF-β<sub>2</sub> led to an increase in the expression of CTGF in ARPE-19 cells. These increases were attenuated by treatment with K-975 and luteolin. These findings suggest that YAP and TAZ may be related to the expression of CTGF in ARPE-19 cells and that K-975 and luteolin can be explored as potential therapeutic agents for preventing CTGF production in vitreoretinal fibrosis.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"246-252"},"PeriodicalIF":2.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD". 回应 FASRS 医学博士 Michael Colucciello 题为 "类固醇/抗血管内皮生长因子联合疗法治疗新生血管性黄斑变性 "的致编辑信。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-04-01 Epub Date: 2024-04-03 DOI: 10.1089/jop.2024.0030
Justus G Garweg, Marlena Pietzuch, Irmela Mantel, Aude Ambresin, Christoph Tappeiner, Dana Nagyova, Guy Donati, Isabel B Pfister, Christin Schild
{"title":"Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled \"Steroid/Anti-VEGF Combination Therapy for Neovascular AMD\".","authors":"Justus G Garweg, Marlena Pietzuch, Irmela Mantel, Aude Ambresin, Christoph Tappeiner, Dana Nagyova, Guy Donati, Isabel B Pfister, Christin Schild","doi":"10.1089/jop.2024.0030","DOIUrl":"10.1089/jop.2024.0030","url":null,"abstract":"","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":"40 3","pages":"199-200"},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor's Letter. 编辑的信
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-04-01 DOI: 10.1089/jop.2024.29122.ujp
Uday Kompella
{"title":"Editor's Letter.","authors":"Uday Kompella","doi":"10.1089/jop.2024.29122.ujp","DOIUrl":"10.1089/jop.2024.29122.ujp","url":null,"abstract":"","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":"40 3","pages":"157"},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Ocular Pharmacology and Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1